drugset / Trial / NCT00909753

Ursodiol 500 mg Tablets Under Fed Conditions

NCT00909753

Phase 1 Completed 92 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to evaluate the comparative bioavailability between Ursodiol 500 mg Tablets (test) and Urso Forte™ 500 mg Tablets (reference)after a single-dose in healthy subjects under fed conditions.

Timeline

Start
2006-09
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 500 mg

Indications

No indication recorded.